Straits Times Index
3,327.68 +1.40 (+0.04%) S&P 500
5,469.30 +21.43 (+0.39%) Dow
39,112.16 -299.05 (-0.76%) Nasdaq
17,717.65 +220.84 (+1.26%) Bitcoin USD
61,471.06 +584.14 (+0.96%) CMC Crypto 200
1,274.96 -8.82 (-0.69%)
VKTX Jun 2024 135.000 call
| Previous close | 0.5500 |
| Open | 0.6500 |
| Bid | 0.0000 |
| Ask | 4.5000 |
| Strike | 135.00 |
| Expiry date | 2024-06-21 |
| Day's range | 0.5500 - 0.6500 |
| Contract range | N/A |
| Volume | |
| Open interest | 264 |
PR NewswireViking Therapeutics Presents Preclinical Data on Novel Dual Amylin and Calcitonin Receptor Agonists at 84th Scientific Sessions of the American Diabetes Association
Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the presentation of preclinical data from a series of internally developed dual agonists of the amylin and calcitonin receptors at the 84th Scientific Sessions of the American Diabetes Association. The presentation highlights the effects of treatment on body weight, food intake and metabolic profile in h
ZacksWhy Viking Therapeutics, Inc. (VKTX) Dipped More Than Broader Market Today
In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $50.43, marking a -0.41% move from the previous day.
Insider MonkeyHere’s Why Viking Therapeutics (VKTX) Stock Skyrocketed in Q1
Wasatch Global Investors, an asset management company, released its “Wasatch Micro Cap Growth—U.S. Strategy” first-quarter 2024 investor letter. A copy of the letter can be downloaded here. During the first quarter, the micro-cap equities performed well. The strategy had a double-digit gain in the quarter, outperforming the Russell Microcap Growth Index benchmark, which rose 6.60%. […]
